Orgenesis Inc. (OTCQX:ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, has announced the acquisition of certain Neurocords LLC’s (“Neurocords”) assets related to advanced regenerative medicine therapies for spinal cord injuries (SCI). Neurocords’ technology now purchased by the Company, differentiates induced pluripotent stem cells (iPSC) into spinal cord neurons leveraging Orgenesis’s decentralized approach to cell processing, which is designed to expedite capacity setup, enhance production efficiency, and reduce treatment costs.
Read the full article: Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening Its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies //
Source: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/orgenesis-inc-announces-acquisition-of-certain-neurocords-llc-assets-s-996914